公开(公告)号：US20170145097A1

公开(公告)日：2017-05-25

申请号：US15424238

申请日：2017-02-03

Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services

Inventor： Dimiter S. Dimitrov ,  Xiaodong Xiao ,  Ira H. Pastan

IPC: C07K16/28 ,  G01N33/574 ,  A61K38/45

CPC classification number: C07K16/2803 ,  A61K38/164 ,  A61K38/45 ,  A61K39/00 ,  A61K39/39558 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6867 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C12Y204/02036 ,  G01N33/57492 ,  G01N2333/70503

Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.

公开(公告)号：US20170081373A1

公开(公告)日：2017-03-23

申请号：US15285830

申请日：2016-10-05

Applicant: VAR2 PHARMACEUTICALS APS

Inventor： Ali Salanti ,  Thor Grundtvig Theander ,  Mads Daugaard ,  Morten Nielsen ,  Madeleine Dahlback ,  Thomas Mandel Clausen

IPC: C07K14/445 ,  C07K14/34 ,  C07K14/21 ,  G01N33/574

CPC classification number: C07K14/445 ,  A61K38/00 ,  A61K38/16 ,  A61K38/45 ,  A61K49/00 ,  A61K49/0056 ,  A61K51/088 ,  C07K14/21 ,  C07K14/34 ,  C07K2319/33 ,  C12Y204/02036 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/47 ,  G01N2333/70585

Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

公开(公告)号：US09598492B2

公开(公告)日：2017-03-21

申请号：US15012023

申请日：2016-02-01

Applicant: The United States of America as represented by the Secretary of the Department of Health and Human Services

Inventor： Dimiter S. Dimitrov ,  Xiaodong Xiao ,  Ira H. Pastan

IPC: A61K39/395 ,  C07K16/28 ,  A61K38/16 ,  A61K47/48 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K38/164 ,  A61K38/45 ,  A61K39/00 ,  A61K39/39558 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6867 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C12Y204/02036 ,  G01N33/57492 ,  G01N2333/70503

Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.

公开(公告)号：US20170058051A1

公开(公告)日：2017-03-02

申请号：US15200629

申请日：2016-07-01

Applicant: Hoffmann-La Roche Inc.

Inventor： ULRICH BRINKMANN ,  EIKE HOFFMANN ,  STEFAN DENGL ,  KLAUS MAYER

IPC: C07K16/44 ,  A61K38/45 ,  C07K16/30 ,  A61K47/48

CPC classification number: C07K16/44 ,  A61K38/45 ,  A61K47/557 ,  A61K47/6817 ,  A61K47/6829 ,  A61K47/6835 ,  A61K47/6879 ,  A61K47/6893 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/94 ,  C12Y204/02036

Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.

Abstract translation: 本文报道了半抗原多肽毒素和抗半抗原抗体的缀合物，其中在用于半抗原缀合的赖氨酸残基之前或之后的半胱氨酸残基之间形成二硫键，并且在CDR2中的半胱氨酸残基 抗体，由此根据Kabat测定CDR2。

公开(公告)号：US20170016905A1

公开(公告)日：2017-01-19

申请号：US15285956

申请日：2016-10-05

Applicant: VAR2 PHARMACEUTICALS APS

Inventor： Ali Salanti ,  Thor Grundtvig Theander ,  Mads Daugaard ,  Morten Nielsen ,  Madeleine Dahlback ,  Thomas Mandel Clausen

IPC: G01N33/574

CPC classification number: C07K14/445 ,  A61K38/00 ,  A61K38/16 ,  A61K38/45 ,  A61K49/00 ,  A61K49/0056 ,  A61K51/088 ,  C07K14/21 ,  C07K14/34 ,  C07K2319/33 ,  C12Y204/02036 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/47 ,  G01N2333/70585

Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

Abstract translation: 本发明涉及包含VAR2CSA的最小结合片段的功能性结合片段，与针对VAR2CSA的这种结合片段的抗体，编码VAR2CSA片段的核酸及其生产方法。 本发明还涉及VAR2CSA多肽的缀合物和融合蛋白，包括最小结合片段及其用途，特别是用于治疗与硫酸软骨素A（CSA）的表达相关的病症，例如硫酸软骨素A（CSA）的不适当表达 ）。

公开(公告)号：US20160347798A1

公开(公告)日：2016-12-01

申请号：US15114474

申请日：2015-01-26

Applicant: MOLECULAR TEMPLATES, INC.

Inventor： Eric Poma ,  Erin Willert

IPC: C07K14/25 ,  C12N9/10 ,  C07K14/245

CPC classification number: C07K14/25 ,  A61K2039/6037 ,  C07K14/245 ,  C07K16/00 ,  C07K16/085 ,  C07K16/088 ,  C07K16/1063 ,  C07K16/286 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/32 ,  C07K2319/04 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/2497 ,  C12N15/62 ,  C12Y204/02036 ,  C12Y302/02022 ,  Y02A50/489

Abstract: The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

Abstract translation: 本发明涉及将一种或多种CD8 + T细胞表位递送到细胞的MHC I类呈递途径的T细胞表位递送多肽，所述多肽包括含有嵌入的T细胞表位的毒素衍生的多肽，并且被免疫 。 本发明提供了细胞靶向的CD8 + T细胞表位递送分子，用于靶向递送对特定细胞（例如感染或恶性细胞）的细胞毒性，用于特异性细胞类型的靶向杀伤，以及各种疾病的治疗， 疾病和病症，包括癌症，免疫疾病和微生物感染。 本发明还提供产生能够将一种或多种异源T细胞表位递送至MHC I型呈递途径的多肽的方法，包括1）B细胞和/或CD4 + T细胞去免疫的多肽，2） 包括嵌入的T细胞表位，和/或3）包含保留毒素功能的毒素效应物。

公开(公告)号：US20160229896A1

公开(公告)日：2016-08-11

申请号：US15098210

申请日：2016-04-13

Applicant: TheVax Genetics Vaccine Co., Ltd.

Inventor： WEI-I CHOU ,  Chia-Mao Wu ,  Jiun-Ming Wu ,  Hsiu-Kang Chang

IPC: C07K14/005 ,  C12N9/14 ,  A61K39/135 ,  A61K39/17 ,  A61K39/12 ,  C12N9/10 ,  C07K14/81

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002 ,  Y02A50/386

Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

Abstract translation: 公开了包含用于诱导增强的病原体抗原特异性T细胞应答的融合蛋白的疫苗组合物。 融合蛋白包括：（a）位于融合蛋白N末端的抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）长度为34-112个氨基酸残基的易位肽，其包含与SEQ ID NO：4,2,3或6至少90％相同的氨基酸序列，位于SEQ ID NO： APC结合结构域或CD91受体结合结构域; 和（c）位于移位肽的C末端的病原体的抗原; （d）包含SEQ ID NO：13的氨基酸序列的核出口信号; 和（e）位于融合蛋白C末端的内质网保持序列。

公开(公告)号：US20160222362A1

公开(公告)日：2016-08-04

申请号：US14889396

申请日：2014-03-31

Applicant: BEIJING BOAUTAI BIOTECHNOLOGY CO., LTD.

Inventor： Junying Zhang ,  Xiaoyun Hou

IPC: C12N9/10 ,  C07K7/23

CPC classification number: C12N9/1077 ,  A61K38/00 ,  A61K38/164 ,  C07K7/23 ,  C07K14/21 ,  C07K2319/55 ,  C12Y204/02036

Abstract: Disclosed are a fusion protein of a human gonadotrophin-releasing hormone mutant (mGnRH) and a pseudomonas aeruginosa exotoxin A mutant (PE38m4a), and a preparation method therefor. The fusion protein can be used for preparing an antitumor drug.

Abstract translation: 公开了人促性腺激素释放激素突变体（mGnRH）和铜绿假单胞菌外毒素A突变体（PE38m4a）的融合蛋白及其制备方法。 融合蛋白可用于制备抗肿瘤药物。

公开(公告)号：US20160193289A1

公开(公告)日：2016-07-07

申请号：US15018991

申请日：2016-02-09

Applicant: Wake Forest University Health Sciences

Inventor： Waldemar Debinski ,  Jill Wykosky ,  Denise Mazess Herpai

IPC: A61K38/17 ,  A61K47/48 ,  A61K38/45 ,  A61K38/20

CPC classification number: A61K38/177 ,  A61K38/00 ,  A61K38/2086 ,  A61K38/45 ,  A61K45/06 ,  A61K47/64 ,  A61K47/642 ,  A61K47/6801 ,  A61K49/0002 ,  C07K14/52 ,  C07K14/705 ,  C12Y204/02036

Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.

公开(公告)号：US20160152724A1

公开(公告)日：2016-06-02

申请号：US14901016

申请日：2014-07-04

Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG e.V ,  RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN

Inventor： Stefan Barth ,  Jenny Fitting ,  Mehmet Kemal Tur

IPC: C07K16/30 ,  G01N33/574 ,  C12N9/10

CPC classification number: C07K16/3061 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/55 ,  C07K2319/60 ,  C12N9/1077 ,  C12Y204/02036 ,  G01N33/57426

Abstract: A polypeptide which binds to the surface of AML blast cells and is internalised upon binding to the AML blast cells.

Abstract translation: 结合AML胚细胞表面并在与AML胚细胞结合后被内化的多肽。